We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-17.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.52B
AUM Growth
-$55.5M
Cap. Flow
+$168M
Cap. Flow %
11.04%
Top 10 Hldgs %
38.58%
Holding
149
New
11
Increased
70
Reduced
43
Closed
11

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$41.6M
2
ILMN icon
Illumina
ILMN
+$33.2M
3
TDOC icon
Teladoc Health
TDOC
+$29.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$25.9M
5
ABT icon
Abbott
ABT
+$14.7M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$17.1M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$15.1M
3
EW icon
Edwards Lifesciences
EW
+$14.5M
4
PACB icon
Pacific Biosciences
PACB
+$13.9M
5
LH icon
Labcorp
LH
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.15%
2 Industrials 0.99%
3 Technology 0.52%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
126
PTC Therapeutics
PTCT
$6.52B
$745K 0.05%
21,700
-800
-4% -$28.8K
GWPH
127
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$626K 0.04%
6,429
-200
-3% -$26.2K
XLRN
128
DELISTED
Acceleron Pharma
XLRN
$623K 0.04%
14,300
-1,900
-12% -$94.9K
HCSG icon
129
Healthcare Services Group
HCSG
$1.74B
$603K 0.04%
15,000
– –
ITCI
130
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$599K 0.04%
52,600
-2,000
-4% -$32.3K
AFMD
131
DELISTED
Affimed
AFMD
$529K 0.03%
+17,000
New +$632K
PTLA
132
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$501K 0.03%
25,650
-1,000
-4% -$20.6K
PINC
133
DELISTED
Premier
PINC
$500K 0.03%
13,400
-1,700
-11% -$70.3K
VAR
134
DELISTED
Varian Medical Systems, Inc.
VAR
$354K 0.02%
3,122
-3,178
-50% -$363K
QURE icon
135
uniQure
QURE
$2.77B
$288K 0.02%
10,000
-9,900
-50% -$275K
VYGR icon
136
Voyager Therapeutics
VYGR
$192M
$262K 0.02%
27,900
-15,522
-36% -$199K
NTLA icon
137
Intellia Therapeutics
NTLA
$1.59B
$216K 0.01%
15,834
-600
-4% -$11.2K
IOVA icon
138
Iovance Biotherapeutics
IOVA
$2.23B
$142K 0.01%
16,000
-9,000
-36% -$86.8K
AGIO icon
139
Agios Pharmaceuticals
AGIO
$2.36B
– –
-19,861
Closed -$1.53M
IBB icon
140
iShares Biotechnology ETF
IBB
$9.23B
– –
-28,000
Closed -$3.41M
PACB icon
141
Pacific Biosciences
PACB
$447M
– –
-2,575,000
Closed -$13.9M
PFE icon
142
Pfizer
PFE
$143B
– –
-30,777
Closed -$1.29M
EGRX
143
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-18,000
Closed -$1.25M
SYNH
144
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-26,156
Closed -$1.35M
TSRO
145
DELISTED
TESARO, Inc.
TSRO
– –
-38,550
Closed -$1.5M
ESRX
146
DELISTED
Express Scripts Holding Company
ESRX
– –
-44,500
Closed -$4.23M
AET
147
DELISTED
Aetna Inc
AET
– –
-7,100
Closed -$1.44M
KTWO
148
DELISTED
K2M Group Holdings, Inc
KTWO
– –
-552,054
Closed -$15.1M
SHPG
149
DELISTED
Shire pic
SHPG
– –
-64,185
Closed -$11.6M
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2018 Portfolio in Review

As of Q4 2018, Bellevue Group held 149 positions worth $1.52B, down 3.5% from $1.58B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group deployed $168M of net new capital in Q4 2018, opening 11 new positions and adding to 70 existing holdings. Its largest new stake was QuidelOrtho: 125,000 shares worth $6.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 93% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Centene, an estimated $17.1M trimmed.

  • Bellevue Group's largest Q4 2018 buy was QuidelOrtho: 125,000 shares worth $6.1M.
  • Bellevue Group added most to Align Technology in Q4 2018, an estimated $41.6M increase.
  • Bellevue Group's biggest Q4 2018 reduction was Centene, cutting an estimated $17.1M.
  • Bellevue Group fully exited K2M Group Holdings, Inc in Q4 2018, selling an estimated $15.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $1.52B portfolio in Q4 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q4 2018.
  • Bellevue Group's portfolio value fell 3.5% quarter-over-quarter to $1.52B.

Based on Bellevue Group's 13F filing for Q4 2018, filed 12 Feb 2019.